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Non-Hodgkin and Hodgkin lymphomas select for overexpression 
of BCLW
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Abstract
Purpose—B-cell lymphomas must acquire resistance to apoptosis during their development. We 
recently discovered BCLW, an anti-apoptotic BCL2 family member thought only to contribute to 
spermatogenesis, was overexpressed in diffuse large B-cell lymphoma (DLBCL) and Burkitt 
lymphoma. To gain insight into the contribution of BCLW to B-cell lymphomas and its potential to 
confer resistance to BCL2 inhibitors, we investigated the expression of BCLW and the other anti-
apoptotic BCL2 family members in six different B-cell lymphomas.
Experimental Design—We performed a large-scale gene expression analysis of data sets 
comprising approximately 2300 lymphoma patient samples, including non-Hodgkin and Hodgkin 
lymphomas as well as indolent and aggressive lymphomas. Data were validated experimentally 
with qRT-PCR and immunohistochemistry.
Results—We report BCLW is significantly overexpressed in aggressive and indolent lymphomas, 
including DLBCL, Burkitt, follicular, mantle cell, marginal zone, and Hodgkin lymphomas. 
Notably, BCLW was preferentially overexpressed over that of BCL2 and negatively correlated 
with BCL2 in specific lymphomas. Unexpectedly, BCLW was overexpressed as frequently as 
BCL2 in follicular lymphoma. Evaluation of all five anti-apoptotic BCL2 family members in six 
types of B-cell lymphoma revealed that BCL2, BCLW, and BCLX were consistently 
overexpressed, whereas MCL1 and A1 were not. Additionally, individual lymphomas frequently 
overexpressed more than one anti-apoptotic BCL2 family member.
Conclusions—Our comprehensive analysis indicates B-cell lymphomas commonly select for 
BCLW overexpression in combination with or instead of other anti-apoptotic BCL2 family 
members. Our results suggest BCLW is likely equally as important in lymphomagenesis as BCL2 
and that targeting BCLW in lymphomas should be considered.
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Introduction
Lymphomas, as with all human cancers, select for alterations that inhibit apoptosis, allowing 
them to survive during transformation (1). The BCL2 family of proteins consists of anti-
apoptotic (BCL2, BCLX/BCL2L1, BCLW/BCL2L2, MCL1, and A1/BFL1) and pro-
apoptotic proteins that regulate cell death (2) and have been linked to many human cancers, 
including lymphomas.
BCL2 translocation to the immunoglobulin locus, leading to BCL2 overexpression, is a 
defining feature of the non-Hodgkin indolent lymphoma follicular lymphoma (FL) (3). 
Diffuse large B-cell lymphoma (DLBCL), an aggressive lymphoma, can also overexpress 
BCL2 (4). Thirty percent of de novo DLBCL have BCL2 translocations and/or increased 
protein expression (5), correlating with reduced survival (4). In contrast to FL and DLBCL, 
Burkitt lymphoma, an aggressive lymphoma, express low/undetectable levels of BCL2, 
which is part of its diagnostics (6). We recently discovered that Burkitt lymphomas 
frequently overexpress BCLW, an anti-apoptotic BCL2 family member that was initially 
reported to only function in spermatogenesis (7,8). Targeting BCLW with shRNA or 
pharmacologically with BH3-mimetics induced apoptosis in Burkitt lymphoma cell lines, 
indicating BCLW was required for its survival (9). When overexpressed, BCLW conferred 
resistance to BH3-mimetics (9). We also showed that DLBCL frequently overexpresses 
BCLW alone or in combination with BCL2, and that increased levels of BCLW in patient 
samples with low BCL2 expression correlated with reduced patient survival (9). Therefore, 
BCLW is a previously unappreciated, significant contributor to Burkitt lymphoma and 
DLBCL, but its involvement in other B-cell lymphomas is unknown.
There are multiple different aggressive and indolent B-cell lymphoma subtypes, but the 
contribution of BCLW and other anti-apoptotic BCL2 family members to them is unclear. It 
is reported that there is increased expression of BCL2 and BCLX in a small subset of mantle 
cell lymphoma (an aggressive lymphoma), whereas MCL1 expression is typically low (10). 
BCL2 levels can be elevated in marginal zone lymphomas, which are indolent (4). Increased 
levels of BCLX were identified in the majority of Hodgkin lymphomas, but are not part of 
its diagnostics (11). Therefore, unlike FL and DLBCL, other B-cell lymphomas have not 
been linked to alterations in specific anti-apoptotic BCL2 family members, which may be 
due to the lack of a comprehensive analysis of these genes/proteins in these lymphomas. 
Here, we evaluated gene expression-profiling data sets of six B-cell lymphomas for the 
expression of BCLW and the other anti-apoptotic BCL2 family members and validated the 
results with qRT-PCR and immunohistochemistry of patient samples. Our data show BCLW 
is frequently overexpressed in all six B-cell lymphomas, suggesting BCLW has an equally 
important role in lymphomagenesis as BCL2. Additionally, most of the lymphomas analyzed 
overexpressed more than one anti-apoptotic BCL2 family member. Our results suggest that 
B-cell lymphomas rely on more than one anti-apoptotic BCL2 family member for their 
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survival. With targeted-therapies against anti-apoptotic BCL2 family members currently 
being tested or developed and therapeutic resistance emerging, our data provide critical 
information that should have significant clinical implications.
Materials and Methods
Microarray gene expression analysis
Thirty-seven microarray gene expression-profiling data sets for six different B-cell 
lymphomas (Burkitt, DLBCL, follicular, mantle cell, marginal zone, and Hodgkin) and 
normal B-cells (germinal center centroblasts and centrocytes, memory B-cells, and CD19+ 
B-cells) were downloaded from the Gene Expression Omnibus (GEO) database (12) or the 
authors’ website (6) (summarized in Supplementary Table 1). The data were generated on 
the Affymetrix Human Genome U133 Plus 2.0 platform following standard Affymetrix 
protocol. The data were separated into batches, normalized using the robust multi-array 
average (RMA) algorithm (13) in the Affy package for R (14). To limit/eliminate 
confounding, we corrected batch effects using ComBat considering two covariates 
(lymphoma and normal) (15). Probe sets were averaged to obtain a single-expression 
intensity measure per gene per array if multiple probe sets corresponded to the same gene 
ID. Expression values from replicate samples were averaged. Differential expression was 
measured using unpaired, one-tailed or two-tailed t-tests as indicated. All analyses were 
carried out in R, version 3.2.3.
Survival analysis
Gene expression profiles and patient clinicopathological information for DLBCL were 
extracted from the GEO database (GSE10846 and GSE31312). Data were normalized and 
probe sets averaged as explained above. Patient samples were simultaneously stratified 
based on the median expression of BCL2 and BCLW into high or low expression groups for 
each gene. Then, patients with low BCL2 expression were identified and Kaplan-Meier 
overall survival curves plotted for the high and low BCLW expression groups and compared 
using log-rank test.
Patient sample acquisition
Patient samples of formalin fixed, paraffin embedded (FFPE) sections were obtained from 
archival pathological specimens at Thomas Jefferson University with approval from the 
Institutional Review Board. Thirty follicular lymphoma, 10 marginal zone lymphoma, 14 
mantle cell lymphoma, 26 Hodgkin lymphoma, and 12 normal lymph nodes were identified 
by a board certified hematopathologist (JZG) and processed as described below for 
evaluation.
RNA isolation and quantitative real-time PCR (qRT-PCR)
Total RNA was isolated from 8 10-μm sections of FFPE tissue using the RecoverAll Total 
Nucleic Acid Isolation Kit as per manufacturer’s instructions (Thermo Fisher). cDNA was 
generated using SuperScript III First-Strand Synthesis (Thermo Fisher) and SybrGreen (SA-
Biosciences) assays were performed in triplicate to measure mRNA expression as previously 
described (16). mRNA expression was normalized to β-ACTIN and presented as 2−ΔΔCt 
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comparing the mean expression of specific mRNA in lymphoma to the mean of this mRNA 
in the controls to determine fold-change. We previously reported the primer sequences for 
BCLW, BCL2, BCLX, and MCL1 (17). Primers for BCL2A1 are forward-5′-
CCCGGATGTGGATACCTATAAGGAGA and reverse-5′-
GTCATCCAGCCAGATTTAGGTTCA.
Immunohistochemistry (IHC)
IHC for BCL2 and BCLW was performed on 4μm FFPE sections from lymphoma and 
control tissues following standard procedures. BCL2 (SP66) and BCLW (ab38629, Abcam, 
1:125 dilution) staining was performed using automated immunohistochemical stainers 
(Ventana Medical Systems and DAKO Autostainer Plus, respectively) according to 
manufacturer specifications. Positive and negative controls were included. Protein levels 
were scored by a practicing, board-certified hematopathologist (JZG) on a 0–3 scale in a 
blinded fashion (representative images in Supplementary Fig. 1).
Statistics
When comparing two groups, two-tailed t-tests were used. For gene expression, qRT-PCR, 
and IHC graphs, lines represent the mean ± SEM and symbols represent individual samples. 
For box and whisker plots, boxes represent the 25th and 75th percentiles, lines indicate the 
median, circles indicate the mean, and whiskers are the maximum and minimum. Survival 
analyses were compared by log-rank tests. Pearson’s correlation coefficient and Spearman’s 
rank correlation coefficient determined the expression correlation between two genes. 
P<0.05 was considered statistically significant unless otherwise noted.
Results
BCLW is overexpressed in activated B-cell (ABC) and germinal center B-cell (GCB) 
subtypes of DLBCL
Recently, after analyzing microarray data sets containing 57 Burkitt and 319 DLBCL patient 
samples, we reported that BCLW is frequently overexpressed in both of these lymphomas 
(9). Since RNA-sequencing data sets were limited, we obtained additional microarray data 
sets of DLBCL and normal human B-cells and combined them with those we previously 
analyzed. Assessing 1490 DLBCL samples showed that BCLW and BCL2 were 
significantly overexpressed compared to normal B-cells (Fig. 1A). These results 
independently validate our previous study and further indicate BCLW is overexpressed in 
aggressive lymphomas, such as DLBCL.
DLBCL has two subtypes, ABC and GCB (18). We evaluated both subtypes for BCLW and 
as a control, BCL2 expression. As previously reported, ABC DLBCL had significantly 
increased BCL2 levels compared to normal B-cells (Fig. 1B and ref. (19)). BCL2 levels 
were also increased in GCB DLBCL, but not to the same extent. In contrast, BCLW was 
equally overexpressed in ABC and GCB DLBCL (Fig. 1B). Further evaluation of ABC 
DLBCL showed that those with higher BCL2 levels had lower BCLW levels and those with 
lower BCL2 levels had higher BCLW levels. This inverse association between BCLW and 
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BCL2 in ABC DLBCL was significant, but not in GCB DLBCL (Fig. 1C, Supplementary 
Table 2, and Supplementary Fig. 2A).
Using two independent data sets containing survival data, we previously reported DLBCL 
patients with high levels of BCLW and low levels of BCL2 had poor survival compared to 
patients whose DLBCL was low for both BCLW and BCL2 (9). To assess whether this was 
specific for ABC or GCB DLBCL, we evaluated overall survival of each subtype based on 
BCLW and BCL2 expression. Although statistical significance was not reached, both data 
sets showed a potential for reduced overall survival for patients with high BCLW and low 
BCL2 in GCB, but not in ABC (Fig. 1D and Supplementary Fig. 2B). Together, our data 
show BCLW is overexpressed in both GCB and ABC DLBCL, and may affect the survival 
of GCB DLBCL.
Indolent lymphomas also select for BCLW overexpression
To ascertain whether selection for BCLW overexpression only occurs in aggressive 
lymphomas, we also evaluated indolent lymphomas. Assessment of patient samples of 
follicular lymphoma (FL; n=196) showed BCL2 was characteristically overexpressed (Fig. 
2A). However, there was also significant overexpression of BCLW compared to normal B-
cells (Fig. 2A). Notably, there was no significant inverse association between BCLW and 
BCL2 expression (Supplementary Fig. 3A), suggesting that BCL2 overexpression was not 
preferentially selected over BCLW. In support of this, of the lymphomas that highly 
overexpressed BCLW (top 25%, n=49), 53.1% also overexpressed BCL2 (Fig. 2B). 
Therefore, BCLW overexpression is selected for even when BCL2 is overexpressed, 
suggesting BCLW is important in FL.
To determine whether the bioinformatic analyses accurately reflected expression in patients, 
we first performed qRT-PCR on patient samples of FL compared to normal lymph nodes. 
BCL2 was significantly overexpressed (Fig. 2C and Supplementary Fig. 3B). BCLW was 
also significantly overexpressed with 93.3% (28 of 30) of the FL expressing at least four-
fold more BCLW than normal lymph nodes (Fig. 2C and Supplementary Fig. 3B). 
Furthermore, consistent with previous reports (20), high-grade FL showed decreased BCL2 
expression compared to low-grade (Fig. 2D and Supplementary Fig. 3C). However, a similar 
level of BCLW overexpression was selected for regardless of grade (Fig. 2D and 
Supplementary Fig. 3C).
We next performed immunohistochemistry (IHC) to assess whether the mRNA levels 
detected were reflected at the protein level. BCLW protein was significantly overexpressed 
compared to normal lymph node (Fig. 2E). Specifically, BCLW staining (≥1 pathologist 
score) was present in all 30 FL assessed, and two-thirds received a score of 2 or 3 (Fig. 2E). 
Characteristically, for FL (21), nearly all showed increased BCL2 levels (Fig. 2E). There 
was a positive correlation between our qRT-PCR and IHC results (Fig. 2F), providing 
additional support that BCLW and BCL2 mRNA expression is reflected at the protein level. 
Together, these results indicate BCLW is overexpressed in FL and that it is overexpressed at 
a similar frequency as BCL2.
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Next, we evaluated 148 patient samples of marginal zone lymphoma (MZL), an indolent 
lymphoma, and determined that both BCLW and BCL2 were overexpressed compared to 
normal human B-cells (Fig. 3A). Notably, there was a significant inverse association 
between BCLW and BCL2 expression (Fig. 3B, Supplementary Table 2, and Supplementary 
Fig. 4A). Measurement of BCLW and BCL2 levels by qRT-PCR in patient samples of nodal 
MZL also showed that both were significantly overexpressed compared to normal lymph 
nodes (Fig. 3C and Supplementary Fig. 4B). Although the average and median expression of 
BCLW was higher than that of BCL2, the negative correlation between the two was not 
statistically significant, likely due to our limited sample set (n=10). Evaluation of BCLW 
protein by IHC showed it was consistently overexpressed, as we detected high levels in MZL 
(average score of 2.2 out of 3). In contrast, although BCL2 protein levels were 
overexpressed compared to normal lymph nodes, BCL2 protein (average score of 1.7 out of 
3) was not as frequently overexpressed as BCLW (Fig. 3D), indicating that BCLW may be 
preferentially overexpressed in nodal MZL over BCL2. A positive correlation was observed 
between the qRT-PCR and IHC analyses for BCLW and BCL2, indicating protein and 
mRNA levels were consistent (Fig. 3E). Therefore, BCLW is overexpressed in indolent and 
aggressive lymphomas.
Mantle cell lymphomas also overexpress BCLW
We evaluated BCLW expression in the aggressive lymphoma mantle cell lymphoma (MCL) 
to determine how widespread BCLW overexpression was. Assessment of 196 MCL samples 
showed significantly increased levels of BCLW and BCL2 compared to normal human B-
cells (Fig. 3F). There was no inverse association between BCLW and BCL2 expression 
(Supplementary Fig. 5A). qRT-PCR analysis of patient samples showed that BCLW and 
BCL2 were both significantly overexpressed in MCL compared to normal lymph nodes (Fig. 
3G and Supplementary Fig. 5B). IHC for BCLW and BCL2 showed increased levels 
(average score of 2.2 and 2.6, respectively, out of 3; Fig. 3H). Furthermore, the mRNA 
expression data and IHC results were positively correlated for both BCLW and BCL2 (Fig. 
3I). Therefore, our data indicate BCLW overexpression is widespread in aggressive and 
indolent non-Hodgkin B-cell lymphomas.
BCLW is overexpressed in Hodgkin lymphomas
To determine whether BCLW overexpression was limited to only non-Hodgkin B-cell 
lymphomas, we evaluated 180 Hodgkin lymphoma (HL) samples. HL showed BCLW 
overexpression compared to normal B-cells (Fig. 4A and Supplementary Fig. 6A). Also, the 
HL with higher BCLW levels had lower BCL2 levels and those with higher BCL2 had lower 
BCLW levels. There was a statistically significant inverse association between their 
expression (Fig. 4B, Supplementary Table 2, and Supplementary Fig. 6A). We evaluated 
patient samples of both nodular sclerosis and mixed cellularity HL by qRT-PCR. Although 
qRT-PCR verified the bioinformatic analyses, showing statistically significant increased 
expression of BCLW and BCL2 mRNA, BCLW was overexpressed significantly more than 
BCL2 in both subtypes (Fig. 4C; Supplementary Fig. 6B and 6C). The preferential selection 
for BCLW overexpression was also observed at the protein level, as 14 of 15 HL samples 
expressed high levels (pathologist score of 2 or 3) of BCLW protein, whereas only 1 sample 
received a high score for BCL2 protein (Fig. 4D). The results of our protein and mRNA 
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analyses were consistent, producing statistically significant positive correlations for both 
BCLW and BCL2 (Fig. 4E). Therefore, HL frequently overexpresses BCLW, and 
preferentially selects for BCLW overexpression over that of BCL2.
Combined, the data show that BCLW is not only overexpressed in Burkitt (9) and DLBCL, 
but it is also overexpressed in follicular, mantle cell, marginal zone, and Hodgkin 
lymphomas. Therefore, BCLW appears to contribute to both indolent and aggressive and 
non-Hodgkin and Hodgkin B-cell lymphomas. Importantly, the data show some lymphomas 
preferentially select for overexpression of BCLW instead of BCL2.
Lymphomas select for the overexpression of multiple anti-apoptotic BCL2 family members
Since we detected increased BCLW expression across all B-cell lymphoma subtypes 
analyzed (Fig. 5A) and there appeared to be preferential BCLW expression in specific 
subtypes, we questioned the expression of the other anti-apoptotic BCL2 family members 
and whether one or more would preferentially be expressed in particular lymphoma 
subtypes. To address this, we evaluated BCLX, MCL1, and A1 expression in the six major 
human B-cell lymphomas (Burkitt, DLBCL, FL, MCL, MZL, and HL). BCLX was 
significantly overexpressed in all six lymphomas compared to normal human B-cells with 
the mean expression highest in DLBCL and lowest in follicular (Fig. 5B). The mean 
expression of MCL1 and A1 was significantly downregulated in Burkitt lymphoma, but 
showed no difference in DLBCL, FL, MZL, MCL, and HL compared to normal B-cells (Fig. 
5C and 5D).
To confirm our bioinformatic results, we performed qRT-PCR on our FL patient samples for 
BCLX, MCL1, and A1. BCLX was significantly overexpressed compared to normal B-cells, 
but MCL1 and A1 were not (Fig. 5E and Supplementary Fig. 7A-C). However, some 
individual FL overexpressed MCL1 or A1 (Supplementary Fig. 7B and 7C). Overall, 
BCLW, BCL2 and BCLX, but not MCL1 or A1, were consistently overexpressed in the 
lymphomas analyzed.
We next assessed whether negative correlations existed between any two anti-apoptotic 
BCL2 family members in the six types of lymphomas. BCLX, MCL1, and A1 showed no 
significant negative correlations with other anti-apoptotic BCL2 family members with three 
exceptions. BCL2 was significantly negatively correlated with MCL1 and BCLX in MZL, 
and BCLW was significantly negatively correlated with A1 in HL (Supplementary Table 2). 
These data suggest preferential section of one anti-apoptotic BCL2 family member over 
another in MZL and HL.
To determine whether individual lymphomas that overexpress BCLW simultaneously 
overexpress other anti-apoptotic BCL2 family members, we selected the top 25% of BCLW-
overexpressing DLBCL samples, which was validated to highly overexpress BCLW 
(Supplementary Fig. 8), and aligned them with the expression of the other four anti-
apoptotic BCL2 family members. We observed 56.8% of the DLBCL samples that 
overexpressed BCLW expressed low (below median) levels of BCL2 (Fig. 6A and 
Supplementary Fig. 8). Notably, a third of the DLBCL samples that overexpressed BCLW 
only overexpressed BCLW and no other anti-apoptotic BCL2 family members (Fig. 6B). 
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However, 36.5% of the BCLW-overexpressing DLBCL samples also concurrently 
overexpressed BCL2, BCLX, MCL1, or A1 (Fig. 6B). Thirty percent of the lymphomas 
simultaneously overexpressed BCLW and two or three other anti-apoptotic BCL2 family 
members, whereas only one BCLW-overexpressing DLBCL also overexpressed the other 
four family members (Fig. 6B).
We expanded our analysis to evaluate the expression patterns of the other anti-apoptotic 
BCL2 family members in FL, MZL, MCL, and HL in the top 25% of BCLW-overexpressing 
lymphomas (Fig. 6C-F). In MZL, MCL, and HL, of the lymphomas that overexpressed 
BCLW, 24.3–33.3% only overexpressed BCLW, whereas only 12.2% of the FL that 
overexpressed BCLW solely overexpressed BCLW. Instead, BCLW-overexpressing FL 
preferentially overexpressed (42.9%) two other anti-apoptotic BCL2 family members (Fig. 
6C). We show that two or more anti-apoptotic BCL2 family members are frequently 
overexpressed together, suggesting that these lymphomas likely rely on more than one for 
survival. Collectively, our data provide evidence that BCLW is a previously unappreciated 
contributor to 6 different B-cell lymphomas and that B-cell lymphomas frequently select for 
the overexpression of BCLW as well as other anti-apoptotic BCL2 family members.
Discussion
Until our recent investigation of Burkitt lymphoma and DLBCL showing that BCLW 
significantly contributes to these lymphomas (9), BCLW was considered only necessary for 
spermatogenesis and dispensable for hematopoietic cells (7,8,22,23). Here, we significantly 
expand upon the lymphomas that select for BCLW overexpression, revealing that both 
aggressive and indolent lymphomas and non-Hodgkin and Hodgkin lymphomas commonly 
overexpress BCLW. Our data show BCLW is overexpressed at a frequency that is similar to 
or greater than, depending on the lymphoma subtype, the quintessential BCL2. 
Unexpectedly, FL, in which BCL2 overexpression is diagnostic, also overexpressed BCLW 
at the same frequency as BCL2 overexpression. We also determined a significant inverse 
association existed between BCLW and BCL2 levels in DLBCL, MZL, and HL, indicating 
these lymphomas preferentially select for overexpression of one over the other. For HL, 
BCLW was preferentially selected for overexpression over BCL2, with samples containing 
high levels of BCLW and low levels of BCL2. A fraction of each lymphoma subtype 
evaluated preferentially selected for BCLW overexpression alone. Together, our results 
indicate that BCLW has a significant role in B-cell lymphomas and is likely as important as 
BCL2.
Our results also provide an unprecedented evaluation of all five anti-apoptotic BCL2 family 
members in the six major B-cell lymphoma subtypes. Analyses of the anti-apoptotic BCL2 
family members revealed overexpression of more than one family member is a frequent 
event in all six lymphoma subtypes evaluated. These data suggest a threshold level of 
expression of BCL2 anti-apoptotic proteins may be needed and once it is reached, 
overexpression of others is not selected for. However, overall, when mean expression levels 
in the six lymphomas were compared to normal B-cells, there appeared to be preferential 
selection for BCLW, BCL2, and/or BCLX overexpression, but not MCL1 or A1. 
Interestingly, in Burkitt lymphoma, the mean expression of MCL1 and A1 was actually 
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lower than their levels in normal human B-cells, suggesting MCL1 and A1 may not 
significantly contribute to this lymphoma. However, in individual lymphomas of all 
subtypes, of those that overexpressed BCLW, a similar low frequency of co-overexpression 
of BCL2, BCLX, MCL1, or A1 was detected. Our data provide evidence that each B-cell 
lymphoma subtype is heterogeneous at the anti-apoptotic BCL2 family level, but most have 
a preference for which family member to overexpress.
Therapies targeted at anti-apoptotic BCL2 family members have entered the clinic. ABT-737 
and ABT-263 (navitoclax), which inhibit BCL2, BCLX, and BCLW showed promise in 
chronic lymphocytic leukemia (CLL) (24). The agents TW-37 and Apogossypolone also 
target multiple anti-apoptotic BCL2 family members (25). However, ABT-263, TW-37, and 
Apogossypolone cause acute cytotoxicity from thrombocytopenia (25), which has led to 
their limited use and the development of compounds only targeting one of the family 
members. The more selective BCL2 inhibitor, ABT-199 (venetoclax) does not deplete 
platelets, but causes neutropenia when used with other drugs (26). Targeting BCL2 with a 
BCL2 anti-sense DNA oligonucleotide (PNT100) leads to lymphopenia (27). The BCLX-
specific inhibitors, A1155463 and A1331852, have been evaluated in non-small cell lung 
cancer (NSCLC), breast cancer, and T-cell acute lymphoblastic leukemia cell lines (28). 
MCL1 targeted therapy has shown single-agent killing of multiple myeloma and NSCLC 
(29). So far, only ABT-199 has been FDA approved for treatment of relapsed or refractory 
CLL (30). Since we have exposed BCLW as a critical contributor to B-cell 
lymphomagenesis, BCLW-specific inhibitors will need to be developed and tested, alone and 
in combination with, other selective BCL2 family inhibitors for future lymphoma treatment.
Despite significant investments into the development of small-molecule therapeutics, many 
compounds still fail in the clinic due to acquired resistance. Resistance mechanisms to 
specific anti-apoptotic BCL2 family inhibitors can occur at least, in part, by overexpression 
of other BCL2 family members. For example, while mantle cell lymphomas are more 
resistant to ABT-199 when they express increased levels of BCLX and MCL1, knockdown 
of MCL1 confers sensitivity to ABT-199 (31). In addition, development of ABT-199 
resistance was linked to increased BCLX and MCL1 levels (BCLW not evaluated) in two 
DLBCL cell lines (32). Additionally, we recently reported that BCLW or BCL2 
overexpression conferred resistance to ABT-263 in Burkitt lymphoma cells (9). Therefore, it 
will be important to monitor other anti-apoptotic BCL2 family members when using 
therapies that target one or more of them.
Our comprehensive evaluation of BCLW and four other anti-apoptotic BCL2 family 
members in six different lymphomas reveals the contribution these genes have to B-cell 
lymphomas by the frequency they are selected for overexpression, individually and with 
each other. Importantly, BCLW overexpression was selected for in all six non-Hodgkin and 
Hodgkin lymphomas evaluated. Furthermore, each of the lymphomas frequently selected 
other anti-apoptotic BCL2 family members to overexpress in addition to BCLW. These 
results illustrate the complexity of treating these lymphomas, as they depend on one or more 
anti-apoptotic BCL2 family members. At a time when inhibitors are actively being 
developed for use in the clinic to target individual BCL2 family members, our analysis 
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demonstrates the importance of considering the expression of all anti-apoptotic BCL2 family 
members for improved targeted therapies and to minimize the occurrence of drug resistance.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Translational Relevance
With clinical trials on-going for BCL2-specific inhibitors for the treatment of lymphomas 
and BCLX- and MCL1-specific inhibitors being developed, there is a critical need for 
increased knowledge of the expression of anti-apoptotic BCL2 family members in 
lymphomas to identify those most likely to respond to specific inhibitors. Our study, the 
first large-scale analysis of all anti-apoptotic BCL2 family members in six types of B-cell 
lymphomas (non-Hodgkin and Hodgkin), reveals B-cell lymphomas typically 
overexpress more than one. Moreover, BCLW, a previously uncharacterized anti-
apoptotic BCL2 family member, was frequently overexpressed. Specific lymphomas 
preferentially selected for BCLW overexpression over that of BCL2. Notably, BCLW was 
overexpressed in follicular lymphoma, indicating it likely has a role in this lymphoma. 
Our results suggest targeting BCLW in B-cell lymphomas may be needed alone or in 
combination with other specific BCL2 family inhibitors, as targeting just one may lead to 
dependence on another resulting in therapy resistance.
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Figure 1. BCLW is overexpressed in GCB and ABC DLBCL
A and B) Gene expression data sets for BCLW and BCL2 mRNA in all DLBCL patient 
samples evaluated (n=1490; A), or stratified based on GCB (n=591) and ABC (n=519) 
DLBCL subtypes (B) compared to normal human B-cells (n=117; A and B). C) Association 
between BCLW and BCL2 mRNA in ABC DLBCL stratified based on the lowest (n=130) 
and highest (n=130) quartiles of BCL2 expression. For A, *P=4.03×10−11 and 
**P=3.00×10−21; B, *P=1.66×10−3 and **P<4.78×10−18; C, *P=1.34×10−5; two-tailed t-
tests. D) Patient samples of GCB DLBCL with low BCL2 from GSE10846 and GSE31312 
data sets were each stratified based on median expression of BCLW into two groups, BCLW 
low and BCLW high. Kaplan-Meier overall survival analyses were performed and compared 
using log-rank tests.
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Figure 2. Overexpression of BCLW is selected for in follicular lymphoma
A) Gene expression data for BCL2 and BCLW mRNA in FL (n=196) compared to normal 
human B-cells (n=117). *P=5.64×10−10 and **P=1.11×10−16; two-tailed t-tests. B) 
Association between BCLW and BCL2 mRNA in FL stratified based on the highest quartile 
(n=49) of BCLW expression. Each line represents one sample. C and D) qRT-PCR analysis 
for BCLW and BCL2, in triplicate, from FL patient samples (n=30) compared with normal 
lymph nodes (n=12) in C (box and whisker plot), or stratified based on grade (low, n=19; 
high, n=11) in D. For C, *P=5.91×10−5 and **P=7.21×10−7; D, *P=0.044 and **P=0.023; 
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two-tailed t-tests. E) IHC analysis for BCLW and BCL2 protein on FL patient samples 
(n=30). Box and whisker plot of pathologist scores and representative images with scores of 
BCLW and BCL2 from the same tumors are shown. F) Pearson correlation coefficients for 
BCLW and BCL2 comparing mRNA fold-change to IHC scores, *P=0.039 and 
**P=1.73×10−6, two-tailed t-tests.
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Figure 3. Marginal zone and mantle cell lymphomas overexpress BCLW
A and F) Gene expression data for BCLW and BCL2 mRNA in MZL (n=148, A) and MCL 
(n=196, F) compared to normal human B-cells (n=117). For A, *P=7.38×10−10 and 
**P=1.29×10−13; F, *P=2.94×10−9 and **P=1.06×10−13; two-tailed t-tests. B) Association 
between BCLW and BCL2 mRNA in MZL stratified based on the lowest (n=37) and highest 
(n=37) quartiles of BCL2 expression; *P=5.13×10−5; two-tailed t-tests. C and G) qRT-PCR 
analysis (box and whisker plot) for BCLW and BCL2, in triplicate, from nodal MZL (n=10, 
C) and MCL (n=14, G) patient samples compared with normal lymph nodes (n=12). For C, 
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*P=5.95×10−3 and **P=8.03×10−5; G, *P=9.28×10−9 and **P=2.01×10−12; two-tailed t-
tests. D and H) IHC analysis for BCLW and BCL2 protein on nodal MZL (n=10, D) and 
MCL patient samples (n=5, H). Box and whisker plots of pathologist scores and 
representative images of BCLW and BCL2 from the same tumors are shown. E and I) 
Pearson correlation coefficients for BCLW and BCL2 comparing mRNA fold-change to IHC 
scores (E, *P=0.024; I *P=0.027, two-tailed t-tests).
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Figure 4. BCLW is preferentially overexpressed in Hodgkin lymphoma
A) Gene expression data for BCL2 and BCLW mRNA in HL (n=180) compared to normal 
human B-cells (n=117). B) Association between BCLW and BCL2 mRNA in HL stratified 
based on the lowest (n=45) and highest (n=45) quartiles of BCL2 expression. For A, 
*P=2.27×10−8 and **P=5.25×10−14; B, *P=4.18×10−5; two-tailed t-tests. C) Box and 
whisker plot of qRT-PCR analysis for BCLW and BCL2, in triplicate, from HL patient 
samples (n=26) compared with normal lymph nodes (n=12). *P=0.013, **P=2.54×10−4, and 
***P=6.26×10−5; two-tailed t-tests. D) IHC analysis for BCLW and BCL2 protein on HL 
patient samples (n=15). Box and whisker plots of pathologist scores and representative 
images of BCLW and BCL2 from the same tumors are shown; arrows indicate HL cells. 
*P=1.43×10−5; two-tailed t-test. E) Pearson correlation coefficients for BCLW and BCL2 
comparing mRNA fold-change to IHC scores, *P=8.49×10−3 and **P=1.10×10−5, two-
tailed t-tests
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Figure 5. Expression of anti-apoptotic BCL2 family members in different B-cell lymphomas
A-D) Gene expression data for BCLW and BCL2 (A), BCLX (B), MCL1 (C), and A1 (D) 
mRNA in the six different lymphomas indicated (BL, Burkitt lymphoma). The data in A is 
summarized from A in Figures 1–4 and 3F. *P<1.0×10−3 is significant except for BL 
(*P<0.01 due to small sample size), two-tailed t-tests. E) Box and whisker plot of qRT-PCR 
analysis for BCLW, BCL2, BCLX, MCL1, and A1 mRNA, in triplicate, from FL patient 
samples (n=30) compared with normal lymph nodes (N; n=12). The data in E for BCLW and 
BCL2 is the same as Figure 2C, but included here for comparison. *P=3.77×10−4, 
**P=5.91×10−5, and ***P=7.21×10−7; two-tailed t-tests.
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Figure 6. Non-Hodgkin and Hodgkin lymphomas preferentially overexpress select anti-apoptotic 
BCL2 family members
A) Gene expression data showing association between BCLW and BCL2, BCLX, MCL1, 
and A1 mRNA in DLBCL stratified based on the top 25% of BCLW expression. Each line 
represents one sample. B) Summarized results of A showing the percentage of samples with 
overexpression of the indicated mRNA within the top 25% of BCLW expression in DLBCL. 
The +2, +3, and +4 indicate the number of additional anti-apopototic BCL2 family members 
that were also overexpressed. C-F, left) Gene expression data showing association between 
BCLW and BCL2, BCLX, MCL1, and A1 mRNA in FL (C), MZL (D), MCL (E), and HL 
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(F) stratified based on the top 25% of BCLW expression. Each line represents one sample. 
C-F, right) Summarized results of left panels showing the percentage of samples with 
overexpression of the indicated mRNA within the top 25% of BCLW expression.
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